Drugs / Mesenchymal progenitor cells
Mesenchymal progenitor cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02641860 | Dec 2015 → Mar 2018 | osteoarthritis | Shanghai AbelZeta Ltd. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Mesenchymal progenitor cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02641860 ↗ |
| Known as | Allogenic Adipose tissue-derived mesenchymal progentior cells | “Biological: Allogenic Adipose tissue-derived mesenchymal progentior cells administrated for intra-articular use” NCT02641860 ↗ |
| Known as | haMPCs | “with allogeneic human adipose-derived mesenchymal progenitor cells (haMPCs) in knee osteoarthritis (KOA) patients.” PMID 31639063 ↗ Oct 2019 |
| Modality | Cell therapy | “allogeneic human adipose-derived mesenchymal progenitor cells (haMPCs)” PMID 31639063 ↗ Oct 2019 |
| Route | Other | “intra-articular injections of haMPCs” PMID 31639063 ↗ Oct 2019 |